Cancer
Commented by Fabian Lorenz on November 3rd, 2022 | 12:01 CET
BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?
BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.
Read
Commented by André Will-Laudien on October 31st, 2022 | 13:31 CET
Top biotech shares - Now on the up: Bayer, Cardiol Therapeutics, BioNTech, Pfizer
The fight against the two "common diseases" of cancer and cardiovascular disease continues with a major infusion of resources. In early 2022, President Biden announced a new edition of the "Cancer Moonshot" and named new goals: To halve the cancer death rate within 25 years and significantly improve the lives of people with cancer. The most common cause of death in Germany, on the other hand, is cardiovascular disease. With around 338,000 deaths in 2020, it accounted for more than a third of the 985,500 deaths. The second most common cause of death was primarily cancer, followed by diseases of the respiratory system. The biotech industry thus continues to face major challenges. Who is well positioned?
Read
Commented by André Will-Laudien on October 13th, 2022 | 14:10 CEST
Attention, turnaround: Bayer, BioNTech, Defence Therapeutics, MorphoSys - These biotech stocks are way down!
Even though more people are being diagnosed with cancer today, and the disease remains the leading cause of death, the number of people dying from cancer is trending downward. In recent years, respectively, survival rates have been steadily increasing. The relative proportion of survivors based on all cancer types in the US has increased from 50% to more than 67% over the past two decades, so today, two out of three patients with a serious disease are still alive after five years. In Europe, too, there has been an increase in 5-year survival rates for the most common cancer types. This is encouraging and draws attention to the oncology sector. Which biotech stocks are significant here and offer a good entry point?
Read
Commented by André Will-Laudien on September 15th, 2022 | 13:35 CEST
Fighting Cancer: BioNTech, Defence Therapeutics, Valneva, MorphoSys - Which biotech stock is ahead in Biden's Moonshot?
Since the original launch of the Cancer Moonshot in 2016, the US cancer community has made measurable progress toward three ambitious goals. Namely, accelerating the scientific discovery of cancer, fostering greater collaboration, and improving cancer data sharing. In early 2022, President Biden announced a relaunch of the Cancer Moonshot and named new goals: To cut the cancer death rate in half within 25 years and significantly improve the lives of people with cancer. The initiative is just getting a new lease on life in the United States. Some biotech shares could make significant gains in this environment.
Read
Commented by Mario Hose on August 18th, 2022 | 10:28 CEST
Defence Therapeutics CEO Sébastien Plouffe on the next steps in the battle against cancer
A publicly traded biotechnology business called Defence Therapeutics is developing new vaccines and antibody-drug conjugates (ADC) products on its own proprietary platform. The ACCUM technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency. CEO Sébastien Plouffe gives us background on the company's latest development in the battle against cancer.
Read
Commented by Armin Schulz on August 9th, 2022 | 13:45 CEST
BioNTech, Defence Therapeutics, Valneva - Will biotech stocks continue to rally in the fall?
The NASDAQ Biotechnology Index formed a double bottom in mid-June and has since rallied, breaking the downtrend. However, there is still over 32% potential to the past highs. The highs are due in part to the sales from the Corona Crisis, but even though currently the issue is not as present despite higher case numbers, that could change in the fall. The new Protection Against Infection Act provides for mask-wearing and further vaccinations. The profits from these sales are often invested in the development of new therapies, such as cancer research. These areas hold a lot of potential for rising share prices. We take a closer look at three biotech companies.
Read
Commented by Mario Hose on August 2nd, 2022 | 10:57 CEST
Defence Therapeutics VP Research + Development Dr. Moutih Rafei on the next generation oncology-targeting therapies
The publicly traded biotechnology company called Defence Therapeutics is developing new vaccines and ADC products on its own proprietary platform. The Accum technology, which enables precise delivery of vaccine antigens or ADCs in their intact form to target cells, forms the basis of Defence Therapeutics' platform. As a result, catastrophic illnesses like cancer and infectious diseases can be combated with greater efficacy and potency.
Read